FIT Biotech Oy: FIT Biotech has demonstrated proof-of-concept of its gene delivery vector in cancer models

FIT Biotech Oy 

Company release April 4, 2017 at 10:15 EET

FIT Biotech has demonstrated proof-of-concept of its gene delivery vector in cancer models

FIT Biotech Oy (“Company”) has met a major research milestone with its new gene delivery vector, gtGTU. Preclinical research in cancer models demonstrated proof-of-concept tumor growth inhibition and improved survival for the new vector platform with two passive immunotherapy gene-based medicines. FIT Biotech has filed a patent application for the new vector platform gtGTU. A scientific publication is currently being prepared.

Delivery and high level and sustained production of naked DNA-based drugs are known to be the main bottlenecks for obtaining efficacy.

Dr. Andres Männik, FIT Biotech’s vice president and head of preclinical research, conducted these studies. He commented, “These initial, highly encouraging results validate the scientific thesis of our gtGTU vector design to increase both the expression level and duration of gene-based medicines. We are looking forward to conducting further studies with collaborators to better understand the therapeutic effect we are observing across other approved biological drugs.”

“We are excited that our preclinical research has demonstrated such remarkable results in preclinical models of cancer using the DNA of known anticancer therapies.  The gtGTU vector may deliver a wide variety of approved and experimental biological therapies at unprecedented lower cost and efficiency,” said Juha Vapaavuori, FIT Biotech’s Chairman “We anticipate engaging in further collaborative research to demonstrate clinical safety and efficacy with other approved biological drugs.”


Board of Directors

For further information:
Chairman of the Board of Directors Juha Vapaavuori
Tel: +358 50 372 0824

Certified Advisor: Aalto Capital Partners Oy, tel. +358 40 587 7000

About FIT Biotech

FIT Biotech Oy is a biotechnology company established in 1995. The company develops and licenses its patented GTU® (Gene Transport Unit) vector technology for new-generation medical treatments. GTU® is a gene transport technology that meets an important medical challenge in the usability of gene therapy and DNA vaccines.

FIT Biotech applies GTU® technology in its drug development programmes. Application areas include cancer (gene therapy) and infectious diseases such as HIV and tuberculosis, as well as animal vaccines.

FIT Biotech shares are listed on the First North Finland marketplace maintained by Nasdaq Helsinki Oy.

Nasdaq Helsinki
Principal media